The findings suggest that beta-blockers and other drugs that help restore balance to the autonomic nervous system may have ...
Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
Tapering. Spaghetti plots show that CSF NFL (right) rises more quickly in people with ADAD mutations (red) than in noncarriers (gray) and that this accelerates as disease progresses. In plasma (left), ...
The Wicked Witch of the West and I have something in common: We both use our fatal flaws to our advantage—for her, her green ...
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
The first patient has begun treatment on a global trial of a novel medication for Huntington's disease, led within the UK by ...
Novartis will make an upfront payment of $1.0 billion to PTCT and the latter will also be eligible for up to $1.9 billion in ...
Madison Elsaadi, an analyst from B.Riley Financial, reiterated the Buy rating on Wave Life Sciences (WVE – Research Report). The associated ...
Common symptoms of Huntington's include uncontrolled movements like jerking and twitching, loss of coordination, difficulty ...
A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa ...